1. Home
  2. NKX vs REPL Comparison

NKX vs REPL Comparison

Compare NKX & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$12.45

Market Cap

645.5M

Sector

Finance

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$10.03

Market Cap

721.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKX
REPL
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
645.5M
721.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
NKX
REPL
Price
$12.45
$10.03
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$12.00
AVG Volume (30 Days)
109.3K
1.7M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
4.37%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.78
$2.68
52 Week High
$12.00
$14.80

Technical Indicators

Market Signals
Indicator
NKX
REPL
Relative Strength Index (RSI) 26.51 57.76
Support Level $12.70 $9.63
Resistance Level $12.80 $10.29
Average True Range (ATR) 0.07 0.59
MACD -0.03 -0.10
Stochastic Oscillator 2.63 35.68

Price Performance

Historical Comparison
NKX
REPL

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: